Global BRCA Mutation-Positive Ovarian Cancer Market Growth, Share, Size, Trends and Forecast (2024 - 2030)

By Indication;

BRCA 1 Ovarian Cancer and BRCA 2 Ovarian Cancer.

By Treatment Type;

Chemotherapy, Targeted Therapies, Anti-Angiogenic Agents, and Poly ADP Ribose Polymerase (PARP) inhibitors.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2020 - 2030).
Report ID: Rn125029164 Published Date: March, 2024 Updated Date: April, 2024

Introduction

Global BRCA Mutation-Positive Ovarian Cancer Market (USD Million), 2020 - 2030

In the year 2023, the Global BRCA Mutation-Positive Ovarian Cancer Market was valued at USD xx.x million. The size of this market is expected to increase to USD xx.x million by the year 2030, while growing at a Compounded Annual Growth Rate (CAGR) of x.x%.

The global market for BRCA mutation-positive ovarian cancer is shaped by the prevalence of BRCA gene mutations, particularly in BRCA1 and BRCA2, which significantly increase the risk of ovarian cancer. This market is driven by a deepening understanding of genetic factors contributing to cancer risk and the development of targeted treatments that address specific molecular pathways linked to BRCA-mutated ovarian cancer.

Advances in genetic testing technologies have enabled earlier detection of BRCA mutations, allowing for personalized treatment strategies and enhanced surveillance for individuals at heightened risk of ovarian cancer due to these mutations. The integration of genetic screening into cancer risk assessment has become pivotal in guiding clinical management and interventions tailored to each patient's genetic profile. Consequently, the global market for BRCA mutation-positive ovarian cancer is witnessing a shift towards precision medicine, focusing on therapies that target the underlying molecular drivers of this specific cancer subtype.

Therapeutic advancements in the market are centered around targeted treatments designed to exploit vulnerabilities associated with BRCA mutations. Poly (ADP-ribose) polymerase (PARP) inhibitors like olaparib and niraparib have demonstrated efficacy in treating BRCA-mutated ovarian cancers by disrupting DNA repair mechanisms unique to these mutations through synthetic lethality. Ongoing research efforts are exploring combination therapies and innovative treatment modalities to further improve outcomes for patients with BRCA mutation-positive ovarian cancer. The evolving landscape of precision oncology and personalized medicine continues to fuel innovation and investment in this specialized market, offering promising prospects for individuals affected by BRCA-associated ovarian cancer.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Indication
    2. Market Snapshot, By Treatment Type
    3. Market Snapshot, By Region
  4. Global BRCA Mutation-Positive Ovarian Cancer Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers:
        1. Genetic Testing and Diagnosis of BRCA Mutations
        2. Treatment Landscape for BRCA Mutation-Positive Ovarian Cancer
        3. Targeted Therapies and Emerging Treatment Approaches
      2. Restraints:
        1. Limited Awareness and Underdiagnosis of BRCA Mutations
        2. High Cost of Genetic Testing
        3. Accessibility to Targeted Therapies
      3. Opportunities:
        1. Increasing Awareness and Education Initiatives
        2. Advancements in Genetic Testing Technologies
        3. Growing Emphasis on Personalized Medicine
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global BRCA Mutation-Positive Ovarian Cancer Market, By Indication, 2022 - 2032 (USD Million)
      1. BRCA 1 Ovarian Cancer
      2. BRCA 2 Ovarian Cancer
    2. Global BRCA Mutation-Positive Ovarian Cancer Market, By Treatment Type, 2022 - 2032 (USD Million)
      1. Chemotherapy
      2. Targeted Therapies
      3. Anti-Angiogenic Agents
      4. Poly ADP Ribose Polymerase (PARP) inhibitors
    3. Global BRCA Mutation-Positive Ovarian Cancer Market, By Geography, 2022 - 2032 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Astrazeneca plc
      2. Merck & Co., Inc.
  7. Analyst Views
  8. Future Outlook of the Market

ReAnIn's Most Viewed Titles:

Healthcare Medical Devices Breathalyzers
Global Breathalyzers Market Growth, Share, Size, Trends and Forecast (2024 - 2030)

In the year 2023, the Global Breathalyzers Market was valued at USD xx.x million. The size of this market is expected to increase to USD xx.x million by the year 2030, while growing at a Compounded Annual Growth Rate (CAGR) of x.x%

Single User License $4200 Read More ...
Healthcare Medical Devices Breast Lesion Localization Device
Global Breast Lesion Localization Device Market Growth, Share, Size, Trends and Forecast (2024 - 2030)

In the year 2023, the Global Breast Lesion Localization Device Market was valued at USD xx.x million. The size of this market is expected to increase to USD xx.x million by the year 2030, while growing at a Compounded Annual Growth Rate (CAGR) of x.x%

Single User License $4200 Read More ...
Healthcare In Vitro Diagnostics Breast MRI Screening
Global Breast MRI Screening Marketet Growth, Share, Size, Trends and Forecast (2024 - 2030)

In the year 2023, the Global Breast MRI Screening et Market was valued at USD xx.x million. The size of this market is expected to increase to USD xx.x million by the year 2030, while growing at a Compounded Annual Growth Rate (CAGR) of x.x%

Single User License $4200 Read More ...
Healthcare Medical Devices Breath Samplers
Global Breath Samplers Market Growth, Share, Size, Trends and Forecast (2024 - 2030)

In the year 2023, the Global Breath Samplers Market was valued at USD xx.x million. The size of this market is expected to increase to USD xx.x million by the year 2030, while growing at a Compounded Annual Growth Rate (CAGR) of x.x%

Single User License $4200 Read More ...